{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T06:00:18Z","timestamp":1773381618217,"version":"3.50.1"},"reference-count":13,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2016,9,5]],"date-time":"2016-09-05T00:00:00Z","timestamp":1473033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc electrophysiol"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:title>Electrocardiographic Abnormalities Associated With Loperamide Abuse<\/jats:title><jats:p>A 20\u2010year\u2010old man presented with recurrent syncope and abnormal electrocardiogram (ECG). His evaluation revealed a prolonged QT interval &gt;600 milliseconds, witnessed torsades de pointes (TdP), and dilated cardiomyopathy. At his initial admission, an ICD was implanted and atrial pacing at 80 beats per minute suppressed ventricular arrhythmias. The patient was readmitted with device infection and recurrent TdP leading to intubation. This led to the discovery of a hitherto unrevealed loperamide abuse and his cardiac arrhythmias and LV dysfunction were determined to be related to large doses of loperamide. Following abstinence, his ejection fraction and ECG returned to normal.<\/jats:p>","DOI":"10.1111\/jce.13052","type":"journal-article","created":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T08:29:13Z","timestamp":1469608153000},"page":"1230-1233","source":"Crossref","is-referenced-by-count":20,"title":["Electrocardiographic Abnormalities, Malignant Ventricular Arrhythmias, and Cardiomyopathy Associated With Loperamide Abuse"],"prefix":"10.1111","volume":"27","author":[{"given":"PATRICIA","family":"VAUGHN","sequence":"first","affiliation":[{"name":"St. Vincent Medical Group  Indianapolis Indiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MICHELLE M. K.","family":"SOLIK","sequence":"additional","affiliation":[{"name":"St. Vincent Medical Group  Indianapolis Indiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHIV","family":"BAGGA","sequence":"additional","affiliation":[{"name":"St. Vincent Medical Group  Indianapolis Indiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"BENZY J.","family":"PADANILAM","sequence":"additional","affiliation":[{"name":"St. Vincent Medical Group  Indianapolis Indiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,9,5]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1540"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563659709001159"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2015.1026971"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.049965"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-008X(03)00372-7"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.109156"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.11.003"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2014.969371"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.05.019"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ccm.0000440506.29056.c1"},{"key":"e_1_2_5_12_1","first-page":"1897","article-title":"Torsades de pointes associated with high dose loperamide ingestion","volume":"6","author":"Marzec LN","year":"2015","journal-title":"J Innov Cardiac Rhythm Manage"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.23.6.802.32186"},{"key":"e_1_2_5_14_1","unstructured":"FDA Drug Safety Communication:FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium) including from abuse and misuse. June 7 2016. Available at:http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm504617.htm.Accessed July 11 2016."}],"container-title":["Journal of Cardiovascular Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjce.13052","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jce.13052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T13:46:21Z","timestamp":1696167981000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jce.13052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,5]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1111\/jce.13052"],"URL":"https:\/\/doi.org\/10.1111\/jce.13052","archive":["Portico"],"relation":{},"ISSN":["1045-3873","1540-8167"],"issn-type":[{"value":"1045-3873","type":"print"},{"value":"1540-8167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,5]]}}}